Aimmune Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
58.48 M |
Public Float |
42.85 M |
Aimmune Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$3.63 |
Market Cap |
$1.3 B |
Shares Outstanding |
62.49 M |
Public Float |
34.21 M |
Address |
8000 Marina Boulevard Brisbane California 94005 United States |
Employees | - |
Website | http://www.aimmune.com |
Updated | 07/08/2019 |
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. |